These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 28858531

  • 61. Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.
    Paul F.
    Expert Opin Pharmacother; 2013 Jan; 14(1):1-3. PubMed ID: 23256603
    [No Abstract] [Full Text] [Related]

  • 62. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
    Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, Gold R.
    Expert Opin Pharmacother; 2013 Oct; 14(15):2145-56. PubMed ID: 23971970
    [Abstract] [Full Text] [Related]

  • 63. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    Adamec I, Brecl Jakob G, Rajda C, Drulović J, Radulović L, Bašić Kes V, Lazibat I, Rimac J, Cindrić I, Gržinčić T, Abičić A, Barun B, Gabelić T, Gomezelj S, Mesaroš Š, Pekmezović T, Klivényi P, Krbot Skorić M, Habek M.
    J Neuroimmunol; 2023 Sep 15; 382():578164. PubMed ID: 37536052
    [Abstract] [Full Text] [Related]

  • 64. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
    Nabizadeh F, Mohamadi M, Rahmani S, Rajabi R, Afrashteh F, Najdaghi S, Mirmosayyeb O.
    Neurol Sci; 2023 Sep 15; 44(9):3045-3057. PubMed ID: 37062787
    [Abstract] [Full Text] [Related]

  • 65. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Schönfelder K, Schuh H, Pfister F, Krämer J, Eisenberger U, Skuljec J, Hackert J, Ruck T, Pfeuffer S, Fleischer M, Gäckler A, Hagenacker T, Kribben A, Meuth SG, Kleinschnitz C, Pul R.
    Mult Scler; 2021 Oct 15; 27(12):1960-1964. PubMed ID: 34165361
    [Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
    Stangel M, Becker V, Elias-Hamp B, Havla J, Grothe C, Pul R, Rau D, Richter S, Schmidt S.
    Mult Scler Relat Disord; 2021 Sep 15; 54():103075. PubMed ID: 34261026
    [Abstract] [Full Text] [Related]

  • 69. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    Zanetta C, Rocca MA, Meani A, Martinelli V, Ferrè L, Moiola L, Filippi M.
    J Neurol; 2023 Jul 15; 270(7):3553-3564. PubMed ID: 37027018
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].
    Hartung HP, Kieseier BC, Aktas O.
    Nervenarzt; 2010 Feb 15; 81(2):194-202. PubMed ID: 20127230
    [Abstract] [Full Text] [Related]

  • 72. Lichenoid rash: A new side effect of oral Cladribine.
    Aruta F, Iovino A, Costa C, Manganelli F, Iodice R.
    Mult Scler Relat Disord; 2020 Jun 15; 41():102023. PubMed ID: 32146431
    [Abstract] [Full Text] [Related]

  • 73. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 15; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Mann H.
    N Engl J Med; 2010 May 06; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
    Avxentyev NA, Davydovskaya MV, Makarova YV, Frolov MY, Klabukova DL.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021 May 06; 121(8):30-36. PubMed ID: 34481433
    [Abstract] [Full Text] [Related]

  • 79. Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis.
    Rau D, Müller B, Übler S.
    Adv Ther; 2023 Dec 06; 40(12):5547-5556. PubMed ID: 37776477
    [Abstract] [Full Text] [Related]

  • 80. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
    Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E.
    Proc Assoc Am Physicians; 1999 Dec 06; 111(1):35-44. PubMed ID: 9893155
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.